CDNA:NSD-CareDx Inc. (USD)

EQUITY | Diagnostics & Research | NASDAQ Global Market

Last Closing

USD 15.53

Change

+0.64 (+4.30)%

Market Cap

USD 0.08B

Volume

0.42M

Analyst Target

USD 44.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CareDx Inc is a commercial stage company. The Company develops, markets and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient's lifetime.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-5.85 (-1.21%)

USD 42.12B
ICLR ICON PLC

+0.36 (+0.12%)

USD 23.70B
ILMN Illumina Inc

+5.07 (+3.72%)

USD 20.73B
NTRA Natera Inc

+3.54 (+2.80%)

USD 15.55B
EXAS EXACT Sciences Corporation

+1.95 (+2.94%)

USD 12.56B
MEDP Medpace Holdings Inc

+5.30 (+1.57%)

USD 10.28B
RDNT RadNet Inc

+1.00 (+1.48%)

USD 5.13B
SHC Sotera Health Co

+0.22 (+1.41%)

USD 4.75B
NEOG Neogen Corporation

+0.13 (+0.87%)

USD 3.61B
GH Guardant Health Inc

+0.36 (+1.65%)

USD 2.82B

ETFs Containing CDNA

ARCG:LSE ARK Genomic Revolution UC.. 7.12 % 0.00 %

+2.05 (+0.43%)

USD 2.87M
ARKG:LSE ARK Genomic Revolution UC.. 6.63 % 0.00 %

+0.02 (+0.43%)

USD 2.96M
XMLH:F Legal & General Ucits Etf.. 2.58 % 0.00 %

N/A

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 2.58 % 0.00 %

N/A

USD 0.07B
DOCG:LSE L&G Healthcare Breakthrou.. 2.48 % 0.00 %

+0.80 (+0.43%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 2.48 % 0.00 %

-0.02 (0.43%)

USD 0.07B
ARKG 0.00 % 0.75 %

N/A

N/A
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

+0.09 (+0.43%)

USD 0.07B
JFWD Jacob Forward ETF 0.00 % 0.00 %

+0.28 (+0.43%)

USD 2.25M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.42% 83% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.42% 83% B 87% B+
Trailing 12 Months  
Capital Gain 53.91% 90% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.91% 90% A- 91% A-
Trailing 5 Years  
Capital Gain -56.06% 50% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.06% 50% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain 17.99% 73% C 77% C+
Dividend Return 17.99% 73% C 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 105.69% 25% F 14% F
Risk Adjusted Return 17.02% 67% D+ 53% F
Market Capitalization 0.08B 66% D+ 70% C-

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 1.69 51% 53%
Price / Cash Flow Ratio -44.08 91% 94%
Price/Free Cash Flow Ratio -2.82 64% 71%
Management Effectiveness  
Return on Equity -54.18% 47% 30%
Return on Invested Capital -29.48% 58% 30%
Return on Assets -12.63% 57% 32%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector